Therapies Addiction therapy goes hand in hand with medication for achieving sustainable recovery from co-occurring disorders
TSLP is differentially regulated by vitamin D3 and cytokines in human skin
GLP-1 receptor agonists (GLP-1 RAs), already established in the management of type 2 diabetes mellitus and obesity, have emerged as promising candidates for the treatment of nonalcoholic steatohepatitis (NASH), owing to their broad metabolic and hepatoprotective effects
In a mouse model of breast cancer, arginine depletion in the TME by macrophages, differentiated in the presence of transforming growth factor beta (TGF), is associated with the inhibition of CD8 + T cells recruitment, due to the enhanced synthesis of collagen
Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)
That is a decision only a physician can make based on your health and history